



Kenvue Inc. (KVUE)

Updated August 6th, 2024 by Nathan Parsh

Key Metrics

Current Price:	\$20.59	5 Year CAGR Estimate:	2.4%	Market Cap:	\$39.4 B
Fair Value Price:	\$16.10	5 Year Growth Estimate:	3.0%	Ex-Dividend Date:	08/14/24
% Fair Value:	128%	5 Year Valuation Multiple Estimate:	-4.8%	Dividend Payment Date:	08/28/24
Dividend Yield:	4.0%	5 Year Price Target	\$19	Years Of Dividend Growth:	62
Dividend Risk Score:	A	Retirement Suitability Score:	A	Rating:	Sell

Overview & Current Events

On May 4th, 2023, Johnson & Johnson (JNJ) completed its split off of its consumer healthcare group, called Kenvue Inc. Kenvue has three segments, including Self Care, Skin Health and Beauty, and Essential Health. Self Care's product portfolio includes cough, cold, allergy, smoking cessation, and pain care products among others. Skin Health and Beauty holds products such as face, body, hair, and sun care. Essential Health contains products for women's health, wound care, oral care, and baby care. Well-known brands in Kenvue's product line up include Tylenol, Listerine, Band-Aid, Neutrogena, Nicorette, and Zyrtec. These businesses contributed approximately 17% of Johnson & Johnson's annual revenue. While Kenvue is a new, standalone business, it carries Johnson & Johnson's 60+ year dividend increase streak.

On July 24th, 2023, Johnson & Johnson announced that it will offer at least 80.1% of its Kenvue stake, roughly 1.5 billion shares, in exchange for JNJ common stock. The parent company currently holds an 89.6% ownership stake in Kenvue. The exchange offer is voluntary for Johnson & Johnson investors as they can elect to exchange all, some, or none of their shares.

On July 25th, 2024, Kenvue announced that it was raising its quarterly dividend 2.5% to \$0.205.

On August 6th, 2024, Kenvue reported second quarter earnings results for the period ending June 30th, 2024. Revenue fell 0.3% to \$4.0 billion, but topped estimates by \$70 million. Adjusted earnings-per-share of \$0.32 matched last year's result, but was \$0.04 better than expected.

Organic sales grew 1.5% for the quarter, which follows a 7.6% improvement last year. For the quarter, pricing and mix benefit of 2.1% was offset by a 0.6% decline in volume. Volume gains in Essential Health were offset by weakness in Skin Health and Beauty and Self Care. Gross profit margin expanded 360 basis points to 59.1%.

Kenvue also reaffirmed prior guidance for 2024. The company continues to expect revenue growth to be in a range of 1.0% to 3.0% and adjusted earnings-per-share in a range of \$1.10 to \$1.20 for the year.

Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
EPS	---	---	---	---	---	---	---	---	---	\$1.29	\$1.15	\$1.33
DPS	---	---	---	---	---	---	---	---	---	\$0.40	\$0.82	\$0.95
Shares¹	---	---	---	---	---	---	---	---	---	1,919	1,920	1,920

Johnson & Johnson produced annual earnings growth of 7% over the last decade as the company's diversification allowed it to be one of the more stable companies in the market place. Kenvue consists of just the consumer products businesses, which were often produced the lowest levels of growth. Therefore, we expect that Kenvue will grow earnings-per-share by 3% annually through 2029.

Johnson & Johnson's dividend growth streak of more than six decades is one of the longest in the market place. The company is both a Dividend King and a Dividend Aristocrat. We believe that penchant for dividend growth is in Kenvue's business DNA. The annualized dividend of \$0.82 per share represents a dividend yield of 4.0%, which is approximately

¹ In millions of shares.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Kenvue Inc. (KVUE)

Updated August 6th, 2024 by Nathan Parsh

three times the average of the S&P 500 Index. We also note that this yield is above Johnson & Johnson's 10-year average yield of 2.7% for additional context.

Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/E	---	---	---	---	---	---	---	---	---	16.0	17.9	14.0
Avg. Yld.	---	---	---	---	---	---	---	---	---	1.9%	4.0%	5.1%

Shares of Kenvue have increased 2.5% since our May 8th, 2024 report. The stock is trading at 17.9 times expected earnings-per-share for 2024. For context, Johnson & Johnson shares have an average price-to-earnings ratio of close to 19 over the last decade. Countering the fact that Kenvue holds some of the industry leading brands with that its products were the lower margin businesses within the parent company, we have a target price-to-earnings ratio of 14.0 for the stock. This implies a headwind from multiple contraction. Therefore, valuation could reduce annual returns by 4.8% through 2029.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	---	---	---	---	---	---	---	---	---	31%	71%	71%

Johnson & Johnson has proven to be one of the most successful companies at navigating recessions. Though Kenvue no longer benefits from its parent company's diversification, we believe that it would prove equally effective at handling economic downturns. The company's products, such as Band-Aid and Tylenol, are needed regardless of the state of the economy as they deal directly with consumers' health and well-being. As trusted products, they would like continue to perform well even under adverse conditions.

Final Thoughts & Recommendation

Following second quarter results, Kenvue is projected to offer an annual return of 2.4% through 2029, down from 2.8% previously. This return stems from 3% earnings growth and a starting yield of 4.0% that are offset by a valuation headwind. After decades as part of Johnson & Johnson, Kenvue became an independent entity early in 2023. The company has produced decent results in its infancy as a standalone company. While we find the legacy business to be recession-resistant and the yield to be generous, the total return profile is unattractive at the current time. We have a five-year price target of \$19 and we continue to view shares of Kenvue as a sell due to projected returns.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Kenvue Inc. (KVUE)

Updated August 6th, 2024 by Nathan Parsh

Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Revenue	---	---	---	---	---	14,324	14,467	15,054	14,950	15,444
Gross Profit	---	---	---	---	---	7,662	7,848	8,419	8,220	8,643
Gross Margin	---	---	---	---	---	53.5%	54.2%	55.9%	55.0%	56.0%
SG&A Exp.	---	---	---	---	---	5,198	4,956	5,484	5,767	6,141
D&A Exp.	---	---	---	---	---	709	746	731	644	627
Operating Profit	---	---	---	---	---	2,399	2,988	3,012	2,469	2,484
Operating Margin	---	---	---	---	---	16.7%	20.7%	20.0%	16.5%	16.1%
Net Profit	---	---	---	---	---	1,435	(879)	2,031	1,455	1,664
Net Margin	---	---	---	---	---	10.0%	-6.1%	13.5%	9.7%	10.8%
Free Cash Flow	---	---	---	---	---	2,709	3,168	39	2,150	2,699
Income Tax	---	---	---	---	---	685	(137)	894	454	526

Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Assets	---	---	---	---	---	---	29,177	27,929	27,358	27,851
Cash & Equivalents	---	---	---	---	---	---	618	740	1,170	1,382
Acc. Receivable	---	---	---	---	---	---	1,858	2,074	2,034	2,073
Inventories	---	---	---	---	---	---	1,685	1,702	2,189	1,851
Goodwill & Int.	---	---	---	---	---	---	21,936	20,511	19,038	18,890
Total Liabilities	---	---	---	---	---	---	10,821	7,530	16,361	16,640
Accounts Payable	---	---	---	---	---	---	1,579	1,827	1,821	2,489
Long-Term Debt	---	---	---	---	---	-	-	-	8,930	8,286
Total Equity	---	---	---	---	---	---	18,356	20,399	10,997	11,211
LTD/E Ratio	---	---	---	---	---	---	-	-	0.81	0.74

Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Assets	---	---	---	---	---	---	---	7.1%	5.3%	6.0%
Return on Equity	---	---	---	---	---	---	---	10.5%	9.3%	10.7%
ROIC	---	---	---	---	---	---	---	10.5%	7.2%	8.4%
Shares Out.	---	---	---	---	---	---	---	---	---	1,919
Revenue/Share	---	---	---	---	---	7.58	7.66	7.97	7.91	8.35
FCF/Share	---	---	---	---	---	1.43	1.68	0.02	1.14	1.46

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.